Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma
Revisit the OncLive On Air Episodes From February 2024
Revisit Every OncLive On Air Episode From April 2024
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer